-
Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint
Friday, January 8, 2021 - 8:50am | 773Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new year, are sinking. What Happened: Cambridge, Massachusetts-based Sarepta announced topline results from Part 1 of the Phase 2/3 study of...